Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease

Muscle and Nerve

Volumn 44, Issue 5, 2011, Pages 720-726

  Banati, Miklos ^a   Hosszu, Zsolt ^a   Trauninger, Anita ^a   Szereday, Laszlo ^a   Illes, Zsolt ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

A glucosidase; Enzyme replacement therapy; Inherited muscle diseases; Late onset glycogenosis ii; Myozyme; Pompe disease; T cell response

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; PERFORIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; ENZYME REPLACEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUNGARY; IMMUNOSTIMULATION; IN VITRO STUDY; NATURAL KILLER CELL; ONSET AGE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ALPHA-GLUCOSIDASES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; LYMPHOCYTE ACTIVATION; MALE;

EID: 80053377114     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22136     Document Type: Article

References (24)

1. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008;372: 1342-1353
2. Xu F, Ding E, Liao SX, Migone F, Dai J, Schneider A, et al. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. Gene Ther 2004;11:1590-1598
3. Sun B, Bird A, Young SP, Kishnani PS, Chen YT, Koeberl DD. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 2007;81:1042-1049
4. Brady RO, Murray GJ, Oliver KL, Leitman SF, Sneller MC, Fleisher TA, et al. Management of neutralizing antibody to ceredase in a patient with type 3 Gaucher disease. Pediatrics 1997;100:111-114
5. Ponce E, Moskovitz J, Grabowski G. Enzyme therapy in Gaucher disease type I: effect of neutralizing antibodies to acid b-glucosidase. Blood 1997;90:43-48
6. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Gen Med 2001;3:132-138
7. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006; 149:89-97
8. Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Görlinger K, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24-31
9. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113:e448-457
10. Kakavanos R, Turner CT, Hopwood JJ, Kakkis ED, Brooks DA. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003;361:1608-1613
11. Corthay A. How do regulatory T cells work? Scand J Immunol 2009; 70:326-336
12. Zhu J, Paul WE. CD4 T cells: fates, functions and faults. Blood 2008; 112:1557-1569
13. Baecher-Allan C, Brown JA, Gordon J, Freeman GJ, Hafler DA. CD4{thorn}CD25high regulatory cells human peripheral blood. J Immunol 2001;167:1245-1253
14. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-530
15. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994;370:650-652
16. Brusko TM, Wasserfall CH, Hulme MA, Cabrera R, Schatz D, Atkinson MA. Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PLoS One 2009;4:e7980.
17. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003;193:70-81
18. Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatments outcomes in Pompe disease infants. Mol Genet Metab 2010;99:26-33
19. Ohashi T, Iizuka S, Ida H, Eto Y. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol Genet Metab 2008;94:313-318
20. Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 2007;120:e37-e46.
21. van der Voort LF, Gilli F, Bertolotto A, Knol DL, Ulitdehaag DM, Polman CH, et al. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch Neurol 2010;67:402-407
22. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
23. Chaves DG, Velloso-Rodrigues C, Oliveira CA, Teixeira-Carvalho A, Santoro MM, Martins-Filho OA. A shift towards a T cell cytokine deficiency along with an anti-inflammatory/regulatory microenvironment may enable the synthesis of anti-FVIII inhibitors in haemophilia A patients. Clin Exp Immunol 2010;162:425-437
24. Hu G, Guo D, Key NS, Conti-Fine BM. Cytokine production by CD4{thorn} T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb Haemost 2007;97:788-794.